Treace to Report Fourth Quarter and Full-Year 2023 Financial Results
PONTE VEDRA, Fla., Feb. 07, 2024 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the fourth quarter and full year of 2023 after the close of trading on Tuesday, February 27, 2024. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET.
Related news for (TMCI)
- Treace Medical Concepts Reports Fourth Quarter and Full-Year 2024 Financial Results
- 24/7 Market News Snapshot 05 November, 2024 – Treace Medical Concepts, Inc. Common Stock (NASDAQ:TMCI)
- Treace Announces Interim 3-Year ALIGN3D™ Clinical Study Data at the 2024 ACFAS Scientific Conference Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure
- Treace to Highlight Latest Product Innovations and ALIGN3D™ Study Outcomes at the 2024 ACFAS Annual Scientific Conference